Download - Glenmark

More documents

Recommendations

Info

Schedules annexed to and forming part of the Balance Sheet (All amounts in millions of Indian Rupees, unless otherwise stated) As at 31 March 2011 As at 31 March 2010 7. INVESTMENTS [Refer Note 14(d) of Schedule 21] Long Term Investments - at Cost - (fully paid except otherwise stated) Quoted - non-trade Equity shares 9,000 (2010 - 9,000) Bank of India of ` 10 each 0.41 0.41 1,209 (2010 - 1,209) IDBI Bank Limited of ` 10 each 0.03 0.03 Investment in government securities National Savings Certificate - Sixth Issue 0.02 0.02 Unquoted - non-trade 1 (2010 - 1) Time share of Dalmia Resorts Limited 0.02 0.02 1 (2010 - 1) Equity Share of Esquados 340,000 of Glenmark Pharmaceutica 0.05 0.05 Limitada, Lisbon (Portugal) 213,032 (2010 - 213,032) Equity Shares of Bharuch Eco - Aqua Infrastructure 2.13 2.13 Limited of ` 10 each 1,350,000 (2010 - 1,350,000) 7% Cumulative Preference Shares of ` 100 each 135.00 135.00 of Marksans Pharma Ltd. Napo Pharmaceuticals Inc. [1,176,471 (2010 - 1,176,471) Preferred shares of 43.56 43.56 USD 0.85 each] Investment in joint venture Glenmark Pharmaceuticals (Thailand) Co. Ltd. [9,800 Ordinary shares of THB 100 each and 16,415 Ordinary shares of THB 100 each (Paid-up THB 50) and 2 Preference shares of THB 100 each (2010 - 9,800 Ordinary shares of THB 100 each and 16,415 Ordinary shares of THB 100 each (Paid-up THB 50) and 2 Preference shares of THB 100 each] 2.51 2.51 Investments in subsidiary companies - unquoted a) Glenmark Exports Limited, India 18.50 18.50 [1,850,020 (2010 - 1,850,020) Equity Shares of ` 10 each] b) Glenmark Impex L.L.C., Russia 901.95 722.29 [577,767,277 (2010 - 455,701,648) Equity Shares of RUR 1 each] c) Glenmark Philippines Inc., Philippines 116.70 116.70 [640,490 (2010 - 640,490) shares of Pesos 200 each] d) Glenmark Pharmaceuticals (Nigeria) Ltd., Nigeria 116.06 86.61 [365,003,963 (2010 - 267,533,341) shares of Naira 1 each] e) Glenmark Pharmaceuticals Malaysia Sdn. Bhd., Malaysia 28.32 15.29 [2,110,342 (2010 - 1,200,861) shares of RM 1 each] f) Glenmark Generics Ltd., India 8,100.25 7,868.00 [144,348,393 (2010 - 143,210,000) shares of ` 10 each] g) Glenmark Holding S. A., Switzerland 797.11 797.11 [22,520,000 (2010 - 22,520,000) shares of CHF 1 each] h) Glenmark Pharmaceuticals (Australia) Pty. Ltd., Australia 65.77 65.05 [1,992,002 (2010 - 1,976,002) shares of AUD 1 each] i) Glenmark Pharmaceuticals Egypt S.A.E., Egypt 71.10 42.94 [8,457,443 (2010 - 4,975,154) shares of EGP 1 each] j) Glenmark Pharmaceuticals FZE (U.A.E.) 12.92 12.92 [1 (2010 - 1) shares of AED 1,000,000 each] k) Glenmark Dominicana, SRL, Dominican Republic 0.06 0.06 [100 (2010 - 100) shares of RD 1000 each] TOTAL 10,412.47 9,929.20 Aggregate book value of Investments - Quoted 0.44 0.44 - Unquoted 10,412.03 9,928.76 Aggregate market value of Quoted Investments 4.46 3.21 58 GLENMARK PHARMACEUTICALS LIMITED
Schedules annexed to and forming part of the Balance Sheet (All amounts in millions of Indian Rupees, unless otherwise stated) As at 31 March 2011 As at 31 March 2010 8. DEFERRED TAX ASSET Provision for bad debts and doubtful advances 69.79 68.02 Others 31.48 28.71 TOTAL 101.27 96.73 9. INVENTORIES [Refer Note 13(f) of Schedule 21] (As certified by the management) Raw materials 625.80 523.45 Packing materials 259.61 154.96 Work-in-process 99.30 182.20 Stores and spares 15.44 16.45 Finished goods (includes Goods in transit) 569.92 626.92 TOTAL 1,570.07 1,503.98 10. SUNDRY DEBTORS [Refer Note 14(b) of Schedule 21] Outstanding for more than six months Secured, considered good - - Unsecured, considered good 1,381.96 2,510.03 Unsecured, considered doubtful 191.10 176.10 1,573.06 2,686.13 Provision for doubtful debts (191.10) (176.10) 1,381.96 2,510.03 Other debts- Secured, considered good - - Unsecured, considered good 1,761.48 4,290.89 1,761.48 4,290.89 3,143.44 6,800.92 Sale of receivable (discounted with recourse) (1,250.00) (3,500.00) TOTAL 1,893.44 3,300.92 11. CASH AND BANK BALANCES Cash in hand 1.90 1.71 Balances with scheduled banks - Current accounts 271.63 32.99 - Margin money account 15.49 14.73 - EEFC account 18.80 0.03 Balances with non-scheduled banks - Current accounts 1.67 1.20 - Deposit accounts - 0.11 TOTAL 309.49 50.77 The balances in the margin money accounts are given as security against guarantees issued by banks on behalf of the Company. Bank balances with Non-Scheduled Banks in Current Account includes: As at 31 March 2011 Maximum amount outstanding during the year 2010-2011 As at 31 March 2010 Maximum amount outstanding during the year 2009-2010 Bank for Foreign Trade of Vietnam 0.36 1.06 0.06 0.40 Imperial Bank 0.11 0.18 0.07 0.22 Foreign Trade Bank of Cambodia 0.01 0.97 0.34 0.48 State Export-Import Bank of Ukraine 0.37 7.28 0.03 1.83 Taib Kazak Bank 0.47 1.90 0.46 0.95 Alp Jamol Bank USD A/c 0.22 0.22 0.22 0.72 Alp Jamol Bank Local Currency A/c 0.01 0.01 0.01 0.52 Asia Alliance Bank 0.12 1.83 - - Bank of Ukraine 0.00 5.83 - - HSBC Singapore USD A/c - 0.02 0.01 0.03 Barclays Bank, New Maadi Branch - - - 0.34 Bank of Kazakhstan USD A/c - 2.61 - 1.22 1.67 1.20 Bank balances with Non-Scheduled Banks in Deposit account includes: HSBC call deposit USD A/c - 0.11 0.11 0.13 Annual Report 2010-2011 59
Page 35 and 36: Profiles of Directors Mr. Gracias S
Page 37 and 38: DIRECTORS Mr. D. R. Mehta, Mrs. B.
Page 39 and 40: 3. Metformin ER Tablets 1000 mg 4.
Page 41 and 42: ANNEXURE - B Disc losure in the Dir
Page 43 and 44: Report on Corporate Governance Purs
Page 45 and 46: 5. Shareholders’/Investors’ Gri
Page 47 and 48: Distribution Schedule as on 31 Marc
Page 49 and 50: Market Price Data: High, low during
Page 51 and 52: Certification by the Chief Executiv
Page 53 and 54: Auditors’ Report To, The Members
Page 55 and 56: (b) The dues outstanding in respect
Page 57 and 58: Profit and Loss Account (All amount
Page 59 and 60: Cash Flow Statement (All amounts in
Page 61: Schedules annexed to and forming pa
Page 65 and 66: Schedules annexed to and forming pa
Page 81 and 82: Additional information as required
Page 83 and 84: Consolidated Statement of Financial
Page 85 and 86: Consolidated Statement of Comprehen
Page 87 and 88: Notes to Consolidated Financial Sta
Page 89 and 90: the foreign entity and translated i
Page 91 and 92: The Group’s internal drug develop
Page 93 and 94: Financial liabilities are recognise
Page 95 and 96: In those cases where the possible o
Page 97 and 98: NOTE B - BASIS OF CONSOLIDATION The
Page 99 and 100: NOTE H - PROPERTY, PLANT AND EQUIPM
Page 101 and 102: Working Capital Facilities is secur
Page 103 and 104: NOTE R - MATERIALS CONSUMED Materia
Page 105 and 106: Net compensated absence cost for th
Page 107 and 108: NOTE Y - SEGMENT REPORTING The Chie
Page 109 and 110: The Group’s trade and other recei
Page 111 and 112: As at 31 March 2011, the Group’s
Page 113 and 114:
Depreciation Further, depreciation
Page 116 and 117:
GLENMARK PHARMACEUTICALS LIMITED Re
Page 118:
GLENMARK PHARMACEUTICALS LIMITED Re
show all

Download - Glenmark

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?